Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DML1KTO)

Drug Name

Belzutifan Drug Info

Synonyms

MK-6482; PT2977

Indication

Disease Entry	ICD 11	Status	REF
Von hippel-lindau disease	5A75	Approved	[1]
Renal cell carcinoma	2C90	Phase 3	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[3]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Hypoxia-inducible factor 2 alpha (HIF-2A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
PT2385	DMCSN69	Recurrent glioblastoma	2A00.00	Phase 2	[4]
------------------------------------------------------------------------------------

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Hypoxia-inducible factor 2 alpha (HIF-2A)	TTDMLNT	EPAS1_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2021. Application Number: 215383.
2	ClinicalTrials.gov (NCT04586231) A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011). U.S. National Institutes of Health.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Hypoxia-inducible factor 2: a novel target in gliomas.Future Med Chem. 2018 Sep 1;10(18):2227-2236.